The Preparation and Biological Evaluation of Some New 6-Iodo-2-Ethyl- 4(3H)-3 (5-Substituted Benzothiazole-2’-Yl) Quinazolinone Derivatives as an Anticonvulsant

Epilepsy is a very common disorder, characterized by seizures, which take various forms and result from episodic neuronal discharges, the form of the seizure depending on the part of the brain affected. Epilepsy affects 0.5-1% of the population. Often there is no recognizable cause, although it may develop after brain damage, such as trauma, infection or tumor growth, or other kinds of neurological disease, including various inherited neurological syndromes. Epilepsy is treated mainly with drugs, though brain surgery may be used for severe cases. Current antiepileptic drugs are effective in controlling seizures in about 70% of patients, but their use is often. It is tendency to experience anticonvulsant agent which blocks experimentally produced seizures in laboratory animal. 6-iodo-2-ethyl-4(3H)-3 (5-substituted benzothiazole-2’-yl) quinazolinones compound were prepared by condensing 5-substituted-2-amino benzothiazoles and 6-iodo-2-ethyl-3, 1-benzoxazine-4-one, then prepared compounds were evaluated for anticonvulsant activity by maximal electroshock method against standard drug like phenobarbitone at 20 mg/ kg dose. The chemical structures of all these compounds were confirmed by Mass, IR, ¹HNMR spectral and elemental analysis. Simultaneously effect of electron donating and withdrawing groups also checked on 6-iodo-2-ethyl-4(3H)-3(5- substituted benzothiazole-2’-yl) quinazolinones.